Titan Medical to Participate in H.C. Wainwright Investor Conference
September 07 2021 - 6:30AM
Business Wire
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device
company focused on the development and commercialization of its
innovative surgical technologies for robotic single access surgery,
today announced that David McNally, President and CEO of Titan
Medical, will present an overview of the company and its Enos™
robotic single access surgical system at the H.C. Wainwright 23rd
Annual Global Investment Conference on Monday, September 13, 2021.
The presentation will be webcast and available on demand starting
at 7:00 a.m. ET. The webcast can be accessed via the Investor
Relations section of the company’s website
www.titanmedicalinc.com.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device
company headquartered in Toronto, Ontario and with R&D
facilities in Chapel Hill, North Carolina, is focused on enhancing
robotic assisted surgery using innovative technology through a
single access point. The Enos™ robotic single access surgical
system is being developed with an ergonomic focus to provide a
surgical experience that imitates real-life movements that surgeons
demand and includes multi-articulating instruments designed to
allow surgeons an increased range of motion in a confined space,
with dexterity and the ability to exert the forces necessary to
complete common surgical tasks. With the Enos system, Titan intends
to initially pursue gynecologic surgical indications. Certain
aspects of Titan’s robotic assisted surgical technologies and
related intellectual property have been licensed to Medtronic plc,
while retaining world-wide rights to commercialize the technologies
for use with the Enos system.
Enos™ is a trademark of Titan Medical Inc.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
company’s future growth, results of operations, performance and
business prospects and opportunities. Forward-looking statements
are frequently, but not always, identified by words such as “may”,
“would”, “could”, “will”, “anticipate”, “believe”, “plan”,
“expect”, “intend”, “estimate”, “potential for” and similar
expressions, although these words may not be present in all
forward-looking statements. Forward-looking statements that appear
in this release may include, without limitation, references to: the
company’s focus on the design and development of surgical
technologies for robotic single access surgery; the company’s
intention to initially pursue gynecologic surgical indications with
the Enos system; and the license of certain of Titan’s robotic
assisted surgical technologies and related intellectual property to
Medtronic plc, while retaining world-wide rights to commercialize
the technologies for use with the Enos system. These statements
reflect management’s current beliefs with respect to future events
and are based on information currently available to management.
Forward-looking statements involve significant risks, uncertainties
and assumptions. Many factors could cause the company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements that may be
expressed or implied by such forward-looking statements, including,
without limitation, those listed in the “Risk Factors” section of
the company’s Annual Information Form and Form 40-F for the fiscal
year ended December 31, 2020 (which may be viewed at www.sedar.com
and at www.sec.gov). Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in the news release are based upon what management
currently believes to be reasonable assumptions, the company cannot
assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking
statements. Except as required by law, the company expressly
disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210907005246/en/
Kristen Galfetti Vice President, Investor Relations &
Corporate Communications +1-781-869-2553
investors@titanmedicalinc.com
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From Apr 2024 to May 2024
Titan Medical (NASDAQ:TMDI)
Historical Stock Chart
From May 2023 to May 2024